Religare Enterprises Limited has informed the Exchange about Transcript
RELIGARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Religare Enterprises reported Q3 FY26 consolidated total income of INR 2,067.9 crores (up from INR 1,670.2 crores YoY) but posted a negative 9M PBT of INR 103.1 crores due to one-time employee benefit provisions. Care Health Insurance (63.2% subsidiary) was the standout, with retail business up 41% YoY, full-premium top line of INR 7,906 crores (21.5% growth), combined ratio improving 110 bps, and a credit rating upgrade from A+ to AA-. Religare Broking PBT jumped 893% to INR 6.6 crores. The big announcement was board approval of a demerger: the financial services business (broking, housing finance, Finvest) will be hived off into Religare Finvest via a 1:1 share swap, with RFL to be separately listed by Q1 FY28; the listed REL entity will retain the entire stake in Care Health. Of the INR 1,500 crore warrants raised, INR 410 crore has been received, with INR 256 crore already deployed into Care Health via rights issue.
The demerger is the key catalyst — it unlocks the holding company discount by creating a pure-play Care Health listed vehicle and a separately listed financial services entity, though execution is 15-18 months away and hinges on regulatory and court approvals. Care Health's improving margins and AA- rating upgrade are positive for the embedded insurance value, but near-term consolidated losses and vague management guidance on future CARE demerger, broking ROE, and legacy recovery targets leave some uncertainty for shareholders.